Form 4: Serina Therapeutics CSO Exercises Options, Sells Shares

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 5,673 shares of common stock.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), completed a transaction on December 22, 2025.
• Exercised 5,673 stock options at an exercise price of $0.06 per share.
• Immediately sold 5,673 shares of common stock at a weighted average price of $2.6737 per share.
• The sale price for the common stock ranged from $2.66 to $2.705 per share.
• Following these transactions, Moreadith beneficially owns 0 shares of common stock directly and 356,286 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction (option exercise and sale) under a 10b5-1 plan, which is neither inherently positive nor negative for the company's operational performance or future prospects. It's a personal financial event for the insider.

Positives

• The exercise of options at a low price ($0.06) and subsequent sale at a significantly higher price ($2.6737) indicates a profitable transaction for the insider.
• The transaction was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on immediate material non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

N/A This Form 4 filing reports a past transaction and does not contain forward-looking statements or guidance.

Industry Context

N/A This is an insider transaction report and does not provide broader industry context.

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative, though mitigated by the 10b5-1 plan and the relatively small number of shares sold compared to remaining options.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider transaction (exercise of options and subsequent sale of shares) by the Chief Scientific Officer. While an insider sale reduces direct equity exposure, the transaction was executed under a Rule 10b5-1 plan, suggesting it was not based on new material non-public information. The number of shares sold (5,673) is a small fraction of the remaining options (356,286), indicating the insider still has significant equity exposure. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it reflects a personal financial event rather than a change in company fundamentals or outlook.

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan